Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects
- 1 September 1995
- journal article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 21 (5), 463-478
- https://doi.org/10.1016/0305-7372(95)90030-6
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI Journal of the National Cancer Institute, 1995
- Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials groupEuropean Journal Of Cancer, 1994
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials groupEuropean Journal Of Cancer, 1994
- Activity of docetaxel (Taxotere) in small cell lung cancerEuropean Journal Of Cancer, 1994
- Taxotere toxicity — Protective effects of premedicationEuropean Journal Of Cancer, 1993
- Effects of taxotere on murine and human tumor cell linesBiochemical and Biophysical Research Communications, 1992
- Effects of antimitotic agents on tubulin-nucleotide interactionsPharmacology & Therapeutics, 1991
- MicrotubulesScientific American, 1980
- MICROTUBULES AS DRUG RECEPTORS: PHARMACOLOGICAL PROPERTIES OF MICROTUBULE PROTEIN*Annals of the New York Academy of Sciences, 1975
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971